Imatinib Amarox (Imatinib)

Imatinib binds to the ATP‑binding pocket of BCR‑ABL, c‑KIT and PDGFR tyrosine kinases, preventing phosphorylation of downstream substrates. This blockade stops proliferative signaling pathways, leading to apoptosis of malignant cells while largely sparing normal tissues.

The dose of Imatinib Amarox is individualized by the treating physician based on the specific indication, disease stage, patient weight, renal and hepatic function, and other clinical factors. Only a qualified prescriber can determine the appropriate regimen.

Safety data for Imatinib Amarox in pregnancy and lactation are limited. The potential risks to the fetus or infant are not well defined, so the drug should only be used if the prescriber determines that the potential benefit outweighs any possible harm.

To place an order, submit an enquiry on the Imatinib Amarox product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Imatinib was the first targeted tyrosine‑kinase inhibitor approved for chronic myeloid leukemia and remains a standard first‑line option. Newer agents such as dasatinib or nilotinib may offer different potency or side‑effect profiles, but imatinib’s long‑term safety record and extensive clinical experience make it a widely used reference therapy.

Imatinib Amarox should be stored at temperatures below 25 °C in its original packaging. Keep the product away from excess moisture, direct sunlight, and sources of heat to maintain stability and potency throughout its shelf life.

Imatinib Amarox is taken orally, usually as a whole tablet with a glass of water. It can be taken with or without food, but consistent administration with respect to meals helps maintain stable absorption. Patients should follow the prescriber’s instructions regarding timing and any dose adjustments.

Serious adverse events include severe neutropenia, hepatotoxicity, cardiac failure, pulmonary hypertension, and rare interstitial lung disease. Patients should be monitored regularly for blood‑count changes, liver‑function abnormalities, and any new cardiac or respiratory symptoms, and report concerns promptly to their healthcare provider.

Imatinib Amarox is contraindicated in individuals with a known hypersensitivity to imatinib or any of its excipients. Caution is also advised for patients with pre‑existing severe liver impairment, uncontrolled heart failure, or those receiving strong CYP3A4 inducers that could markedly reduce drug exposure.